0.96 USD
↘ 0.01 (0.57%)AT CLOSE (03:59 PM EDT)
IN8bio, Inc. Common Stock
INABNASDAQ • USD
0.97
↗ 0.01 (0.52%)
POST MARKET (AS OF 04:00 PM EDT)
Post Market
AS OF 04:00 PM EDT
0.97
↗ 0.01 (0.52%)
Market: OPEN
IN8bio, Inc. Common Stock (INAB) trades at $0.97 per share. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Oct 27, 2026.
Open?$0.95
High?$0.99
Low?$0.93
Prev. Close?$0.97
Volume?12.2K
Avg. Volume?50.1K
VWAP?$0.97
Rel. Volume?0.24x
Bid / Ask
Bid?$0.80 × 100
Ask?$1.25 × 100
Spread?$0.45
Midpoint?$1.02
Valuation & Ratios
Market Cap?9.6M
Shares Out?9.9M
Float?7.0M
Float %?71.4%
P/E Ratio?N/A
P/B Ratio?0.52
EPS?-$1.89
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Employees
18
Market Cap
9.5M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2021-07-30
Address
EMPIRE STATE BUILDING
NEW YORK, NY 10118
Phone: (646) 600-6438
NEW YORK, NY 10118
Phone: (646) 600-6438
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?77
Short Sent.?100
Piotroski F-Score?0/9Weak
Altman Z-Score?-10.04Distress
Confidence?43%Low
Short InterestLow
Short % of Float?0.47%Low
Short Interest?32.8K
Days to Cover?1.0
Free Float7.0M
Avg Daily Volume46.4K
Settlement Date2026-10-15
Financial Health
Current Ratio?8.21Strong
Quick Ratio?8.21Strong
Cash Ratio?7.97Strong
Debt/Equity?0.01Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?0.52CHEAP▾
Peers100
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?0.5CHEAP▾
Peers100
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-101.7%WEAK▾
S&P3
ROA?-85.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-14597000
Enterprise Value?$-8267368
Fundamentals ratios updated end of day